Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Tuesday, July 14, 2026

Snapshot: Jul 14, 2026 · 6:00 PM 100 stocks analyzed

Up Day

Tue, Jul 14, 2026 Divergent Normal

S&P 500 edged up 0.53% in a divergent, stock-pickers' day marked by extreme single-name volatility—mergers, earnings misses, and FDA wins driving triple-digit gainers alongside …

55% Individual stock catalysts and deal activity dominated price action, with NXTC soaring 202% on a merger announcement, IBM cratering 25% on a guidance miss, and healthcare/financials leading gainers while tech fragmented between winners and losers; the story was stock-picking, not index direction.
30% Divergent regime and narrow index advance reflected competing forces—NASDAQ +1.12% and NASDAQ-100 +1.42% outpaced S&P 500 +0.53%, while Dow fell 0.79% and Russell 2000 dropped 0.59%, signaling no clean risk-on or risk-off theme and leaving investors navigating conflicting signals across cap sizes and sectors.
15% Sector rotation showed healthcare leading gainers with 27.5% of top 50, while technology dominated losers with 21.7%, and a wave of five new debutants entered top gainers after long absences, suggesting fresh deal flow and earnings beats were reshaping the leadership map in early July trading.

5 names returned after long absences VTAK · 4-day losers streak DFNS · 3-day losers streak LEDS — first appearance ARBE — first appearance

Market Regime

Tue, Jul 14, 2026 Neutral conf: low macro · prototype

+15

Tailwind −100 … +100 · + tailwind / − headwind

VIX16.5 Drawdown-0.9% Held6d · building SinceJul 7

Top drivers: S&P drawdown (60d) ▲ S&P vs 20d avg ▲ S&P vs 50d avg ▲

processId: history-market-regime

Market Indexes

Tue, Jul 14, 2026 13

S&P 500

7,543.59

+39.74

+0.53%

Dow Jones

52,508.27

−416.88

-0.79%

NASDAQ Composite

26,107.01

+288.32

+1.12%

NASDAQ 100

29,586.29

+413.27

+1.42%

DJ US Total Market

74,733.26

+304.24

+0.41%

Russell 1000

4,108.29

+16.28

+0.40%

S&P MidCap 400

3,777.26

+5.49

+0.15%

Russell 2000

2,964.76

−17.73

-0.59%

Russell 2500

1,259.84

+4.80

+0.38%

Russell 3000

4,290.13

+15.19

+0.36%

Nasdaq Financial-100

7,457.08

−9.52

-0.13%

NIFTY 50

24,052.05

+170.00

+0.71%

VIX

16.50

−0.40

-2.37%

Biggest Gainers

Tue, Jul 14, 2026 50

NXTC

NextCure, Inc.Healthcare

$6.58+$4.40

+201.8%

NASDAQ · Mkt cap $31 M

NextCure announced a merger with Avere Therapeutics on July 14, 2026, combining Avere's oral IL-23 therapy candidate AVR-001 with NextCure's pipeline, driving a 201.83% gain on the news of the strategic combination.

The July 14 news headline explicitly announces that NextCure and Avere Therapeutics have agreed to merge, with Avere's lead program AVR-001 described as a differentiated oral peptide IL-23 receptor antagonist showing Phase 1b psoriasis data. This is a material M&A event—a merger announcement of two clinical-stage biotech companies combining their assets and pipelines. For a small-cap biotech stock like NextCure trading at $6.58, a merger announcement with a partner bringing a Phase 1b clinical candidate represents significant value creation or restructuring that markets typically reward on the announcement day. The late-afternoon healthcare sector decline mentioned in a separate headline does not appear to have dampened the stock's response, suggesting the merger news was the dominant factor driving the trading decision on July 14.

CNEY

CN Energy Group. Inc.Basic Materials

$0.75+$0.27

+56.3%

NASDAQ · Mkt cap $5.0 M

No news headlines were found in the last 48 hours, so the 56% gain cannot be attributed to a specific announced catalyst. The move is likely driven by technical factors, delayed market reaction to older news, or unconfirmed speculation.

CNEY jumped 56% on July 14, 2026, but no recent headlines are available to explain the move. This is a low-priced stock trading on NASDAQ at $0.75, which makes it potentially susceptible to technical trading, short squeezes, or retail speculation. Without access to earnings announcements, contract wins, regulatory approvals, or strategic updates from the past 48 hours, the underlying cause remains unclear. The absence of news coverage despite the large percentage move suggests either that the catalyst predates the 48-hour window, that the move is driven by momentum or technical patterns rather than fundamental news, or that market participants are reacting to information not yet reflected in major financial news feeds. Small-cap energy stocks can be volatile, and CN Energy Group's low share price may amplify intraday swings relative to the underlying company developments.

VEEE

Twin Vee Powercats Co.Consumer Cyclical

$38.51+$13.65

+54.9%

NASDAQ · Mkt cap $6.2 M

Twin Vee PowerCats announced a definitive merger agreement with a USFM Corporation subsidiary on July 13, triggering a surge that carried into July 14 trading as the market digested the transformative transaction and concurrent privatization plan.

On July 13, 2026, Twin Vee PowerCats disclosed a strategic merger with a subsidiary of USFM Corporation, paired with plans to separate and privatize its recreational marine business. The headline data shows initial intraday volatility on July 13 itself—reports cite surges ranging from 85% to over 370% depending on the time and measurement—followed by the continued 54.91% gain on July 14. This suggests two possible dynamics: either the July 14 move reflects fresh buying momentum and continued processing of the deal's strategic value, or the earlier headline percentages were measured from an intraday low rather than previous close, making the July 14 figure a partial consolidation. The merger appears to be viewed as transformative, implying investor optimism about the combined entity or the separation strategy. Without full details on valuation, deal structure, or market reaction nuance, the sustained upward pressure across both days points to sustained conviction in the transaction's merits.

AMPGR

Amplitech Group, Inc. Series A Right

$1.84+$0.61

+49.2%

NASDAQ

No news was reported in the last 48 hours, making the 49% jump difficult to attribute to a specific catalyst. The move may reflect technical trading, short covering, or a delayed market reaction to an untracked announcement.

The absence of any headlines in the 48-hour window prior to this 49% surge is notable and limits our ability to identify a concrete cause. Amplitech Group Series A Rights are a specialized security instrument tied to reorganization or rights offerings, which can experience outsized volatility on low volume and limited liquidity. For this class of security, possible catalysts include technical rebalancing, short squeeze activity if the float is tight, shareholder voting outcomes, or clarifications regarding the terms or timing of the underlying rights. Without verifiable news, any explanation remains speculative. Rights offerings and special securities are often traded by sophisticated investors responding to corporate action timelines or regulatory filings that may not immediately surface in public headlines.

LEDS

SemiLEDs CorporationTechnology

$2.24+$0.72

+47.4%

NASDAQ · Mkt cap $18 M

SemiLEDs announced third quarter fiscal 2026 earnings on July 14, likely driving a 47% single-day surge as the market reacted to the financial results and company performance.

SemiLEDs released its Q3 fiscal 2026 results on the morning of July 14, which coincides precisely with the stock's massive 47% gain and fifth-place ranking among daily gainers. The headline confirms only that financial results were announced but does not disclose specific metrics, guidance, margins, revenue growth, or year-over-year comparisons. Without access to the full earnings release or management commentary, we cannot confirm whether the move reflects a revenue or earnings beat, upside guidance revision, margin expansion, new customer wins, or other positive drivers. However, for a micro-cap LED chip manufacturer trading at $2.24, earnings announcements that surprise positively (or reverse prior negative sentiment) can trigger outsized percentage moves. The timing match between the 09:00 UTC announcement and the day's close is consistent with earnings-driven reaction.

CRMT

America's Car-Mart, Inc.Consumer Cyclical

$4.28+$1.26

+41.7%

NASDAQ · Mkt cap $27 M

America's Car-Mart reported better-than-expected adjusted earnings per share for Q1 2026 despite missing revenue expectations and a 17.9% year-over-year sales decline, triggering a 41.72% surge as the market rewarded profitability and operational efficiency focus.

The earnings announcement on July 14, 2026 revealed a mixed picture that initially appears contradictory but explains the rally. While CRMT missed revenue expectations with Q1 sales falling 17.9% to $302.8 million, the company delivered non-GAAP earnings of $0.48 per share that beat analyst forecasts. Multiple news sources confirm the stock jumped materially (4.7% to 9.2%) during the day following this report. The headlines emphasize that despite challenges in unit sales and revenue, management is focusing on liquidity strengthening and operational efficiency improvements. The market appears to have rewarded the earnings beat and evidence of disciplined cost management in a difficult environment, viewing this as a positive signal about the company's ability to remain profitable through headwinds. This suggests investors prioritized margin performance and operational execution over top-line growth in this particular instance.

SHPH

Shuttle Pharmaceuticals Holdings, Inc.Healthcare

$4.16+$1.20

+40.5%

NASDAQ · Mkt cap $2.3 M

No news headlines were found in the last 48 hours, so the 40.54% gain cannot be directly attributed to a reported event. The move likely reflects technical factors, delayed news dissemination, or undisclosed market information.

Shuttle Pharmaceuticals is a small-cap biopharmaceutical company, and the absence of any news in the past 48 hours despite a substantial single-day rally is notable. For companies in this sector and size range, a 40% move typically correlates with material clinical data, regulatory decisions, partnership announcements, or financing news. The lack of captured headlines suggests either that the catalyst occurred before the 48-hour window, that news has not yet propagated to major feeds, or that the move was driven by technical factors such as short covering, options-related gamma hedging, or algorithmic repositioning. Without visibility into order flow or insider information, pinpointing the exact cause is not possible from available evidence.

FXHO

UTime LimitedTechnology

$20.86+$5.26

+33.7%

NASDAQ · Mkt cap $54 M

No news headlines were published in the last 48 hours for FXHO, so the 33.72% gain cannot be directly attributed to a disclosed catalyst. The jump likely reflects a technical or market-driven event.

The absence of any recent news headlines is striking given the magnitude of the move, which ranks FXHO as the eighth biggest gainer on the day. For a stock to surge over 33 percent without accompanying news coverage suggests either a delayed market reaction to an older announcement not captured in the 48-hour window, a technical bounce from oversold conditions, short covering if the stock is heavily shorted, retail trading momentum, or a low-float dynamic where thin liquidity amplifies price moves. Without access to intraday catalysts, SEC filings, or broader market context for UTime Limited specifically, the actual driver remains speculative. The gap between the price action and news silence is notable and warrants deeper investigation into the company's recent disclosures and trading patterns.

BMGL

Basel Medical Group Ltd Ordinary SharesHealthcare

$8.12+$1.98

+32.2%

NASDAQ · Mkt cap $8.1 M

BMGL surged 32.25% on July 14, 2026, but no news headlines were found in the prior 48 hours, making the specific catalyst unclear. The move may reflect delayed announcement pickup, technical trading, or undisclosed developments.

No recent news headlines were available to explain the sharp 32% rally in BMGL. Without documented earnings beats, regulatory approvals, partnership announcements, or guidance changes in the provided sources, the precise catalyst remains unknown. Basel Medical Group is a small-cap medical device or diagnostic company traded on NASDAQ, and such stocks can experience significant single-day moves on several categories of events: delayed media pickup of company announcements, clinical trial results or regulatory decisions that may have been released but not yet syndicated to major financial news feeds, short covering or technical breakouts, sector rotation effects, or undisclosed insider activity. The absence of headlines in the 48-hour window does not rule out that news did break; it may indicate either a gap in the news feed provided or a genuinely unheralded move driven by technical factors or retail trading interest.

ARBE

Arbe Robotics Ltd.Technology

$0.87+$0.19

+27.0%

NASDAQ · Mkt cap $94 M

Arbe Robotics announced selection of its radar technology by a leading global defense system integrator for multiple civilian and defense programs, likely triggering the 27% intraday gain as a validation of commercial traction in high-value markets.

The headline released on July 14 at 12:00 UTC describes a concrete contract selection win for Arbe's radar technology by a major defense and homeland security system integrator. While the announcement does not specify contract value, duration, or exact program details (the full press release text is truncated), this type of news typically signals validation of the company's technology roadmap and entry into large institutional customer relationships. For a micro-cap radar specialist, selection by a "leading global" defense integrator for "multiple" programs represents material revenue optionality and reduces technology-risk perception. The timing of the announcement aligning with the price jump strongly suggests this is the primary driver, though without forward revenue guidance or quantified program scope, investors may be reacting to strategic positioning rather than immediate financial impact.

PDC

Perpetuals.com LtdTechnology

$4.06+$0.85

+26.5%

NASDAQ · Mkt cap $21 M

Perpetuals.com announced termination of acquisition talks with a Trump-linked crypto firm on July 14, and the market responded with a +26.48% gain, suggesting investors viewed the deal's collapse as positive or the company's strategic repositioning as favorable.

On July 14, 2026, Perpetuals.com issued formal statements terminating a Letter of Intent with AI Financial Corporation and ending acquisition discussions with a World Liberty Financial-affiliated entity. The timing of these announcements—both published within hours on the same day—coincides precisely with PDC's 26.48% jump to rank 11 biggest gainer. Investors may have perceived the deal termination as prudent risk management, particularly given the crypto sector's regulatory uncertainties and the Trump-family association potentially carrying reputational or compliance risk. Alternatively, the market may have viewed the company's ability to walk away as a sign of financial stability and strategic discipline. Without additional commentary from management on future plans or valuation impacts, the exact interpretation remains somewhat ambiguous, but the directional signal is clear: deal termination was priced as good news.

AMPGZ

Amplitech Group, Inc. Series B Right

$1.25+$0.26

+26.3%

NASDAQ

No news headlines were found in the last 48 hours, so the 26% gain in this Series B rights offering likely reflects either a delayed market reaction to a prior announcement, technical trading activity, or corporate action related to the parent company Amplitech Group.

The absence of recent news headlines makes it difficult to pinpoint a specific catalyst for today's 26% rally in AMPGZ, which is a Series B rights offering rather than common equity. Rights offerings are typically sensitive to the underlying company's stock performance and investor sentiment about the parent entity's prospects. Possible explanations include a delayed positive announcement from Amplitech Group itself that has now gained broader market awareness, a short squeeze or thin-liquidity rally in this illiquid security, or news about the company's RF semiconductor or microwave component business that has not yet surfaced in the RSS feed checked. Without current headlines or knowledge of Amplitech's recent corporate actions or earnings calendar, it is honest to acknowledge that this move's primary driver remains unclear.

PHOE

Phoenix Asia Holdings Limited Ordinary SharesIndustrials

$25.95+$5.25

+25.4%

NASDAQ · Mkt cap $526 M

No news headlines were found in the last 48 hours, so the 25.36% gain cannot be attributed to a specific announced event. The move likely reflects either delayed market reaction to earlier news, technical/momentum factors, or undisclosed catalysts.

Phoenix Asia Holdings Limited jumped 25.36% to rank as the 13th biggest gainer on the day, but zero news headlines appeared in the last 48 hours to explain the surge. This absence of concurrent news coverage is notable for such a large single-day move. Possible explanations include a delayed market reaction to an earnings release or corporate announcement that predates the 48-hour window, short-covering or technical momentum in a thinly traded small-cap stock, or a catalyst that broke but was not yet picked up by Yahoo Finance's RSS feed. Without access to intraday news flow, trading halt information, or the stock's ownership structure, we cannot determine whether this reflects fundamental news, technical activity, or sentiment shifts.

CRWL

GraniteShares 2x Long CRWD Daily ETF

$75.78+$14.53

+23.7%

NASDAQ

No news headlines were found in the last 48 hours, but CRWL is a 2x leveraged ETF tracking Crowdstrike, so a ~12% move in the underlying stock would produce roughly this +23.72% daily gain through mechanical amplification.

The lack of recent news headlines makes direct attribution impossible. However, CRWL is a daily reset 2x long leveraged ETF on Crowdstrike Holdings (CRWD). A leveraged ETF of this type amplifies daily moves of its underlying by a factor of two before accounting for compounding effects and tracking decay. A ~10-12% rally in CRWD stock itself would mechanically translate to approximately this magnitude of gain in CRWL. Without access to Crowdstrike's stock price or news on that security for July 14, 2026, the most probable explanation is strong upward movement in the underlying CRWD stock, which could stem from earnings, product announcements, broader cybersecurity sector strength, or market-wide risk-on sentiment. The absence of CRWD-specific news here does not mean no catalyst occurred—it may simply be that the news has not yet been indexed by the RSS feed sampled.

DMIIR

Drugs Made In America Acquisition II Corp.

$0.10+$0.02

+23.5%

NASDAQ

No news headlines were found in the last 48 hours for DMIIR, so the 23.46% gain likely stems from technical factors, delayed news flow, or retail speculation typical of low-priced SPAC stocks rather than a specific announced catalyst.

DMIIR is a blank-check acquisition company (SPAC) trading at $0.10, a micro-cap price point where small absolute dollar volume moves can produce large percentage swings. The absence of any news in the last 48 hours means the jump cannot be attributed to earnings, FDA action, M&A news, or guidance changes. For SPACs at this price and stage, gains often reflect either technical chart movements, delayed reporting of previous announcements, retail trading activity, or sector-wide momentum in blank-check equities. Without access to real-time Level 2 data or knowledge of prior-week events, pinpointing the precise trigger is not possible from the information provided.

NIXX

Nixxy, Inc.Communication Services

$1.40+$0.26

+22.8%

NASDAQ · Mkt cap $21 M

No news headlines were found in the last 48 hours for Nixxy, Inc., so the 22.81% jump likely stems from technical factors, delayed news dissemination, or unconfirmed market rumors rather than a confirmed corporate event.

The absence of any Yahoo Finance headlines in the past two days is notable given the stock's ranking as the 16th biggest gainer. This suggests either the catalyst has not yet been formally reported through mainstream financial news feeds, or the move is driven by technical factors such as short covering, options expiration effects, or intraday volatility. For a stock trading at $1.40, which may indicate a micro-cap or distressed issuer, price action can be volatile and driven by retail interest, technical breakouts, or unconfirmed rumors circulating in less-monitored channels. Without specific news, the most plausible categories of catalyst would be a delayed earnings announcement, an unannounced contract or partnership, insider activity, or broader sector momentum. However, none of these can be confirmed from the provided information.

BMNG

Leverage Shares 2x Long BMNR Daily ETF

$13.13+$2.41

+22.5%

NASDAQ

No news headlines were found in the last 48 hours, but BMNG is a 2x leveraged long ETF tracking BMNR, so a 22.48% gain likely reflects a significant rally in the underlying asset amplified by its 2x daily reset mechanism.

The absence of recent news does not rule out a concrete cause for the move; it simply means the trigger is not visible in the headline feed provided. BMNG is a leveraged ETF designed to deliver twice the daily return of its benchmark (BMNR). A 22.48% gain in BMNG would imply roughly an 11% gain in the underlying BMNR, which is substantial. The most likely explanations fall into two categories: first, BMNR itself rallied sharply in response to company-specific news, sector strength, or market sentiment—any of which would be amplified 2x by the ETF structure. Second, the move could reflect technical factors such as rebalancing flows, options activity, or short covering in the underlying. Without visibility into BMNR's news or price action, or into the mechanics of BMNG holdings, the specific trigger remains opaque.

LHAI

Linkhome Holdings Inc.Real Estate

$1.22+$0.22

+22.0%

NASDAQ · Mkt cap $12 M

Linkhome Holdings announced the commercial launch of its OpenLink AI platform and signed a US$10.5 million two-year enterprise AI compute services agreement, driving a 22% gain on strong investor enthusiasm for revenue-generating AI infrastructure.

The stock's jump ranks it as the 18th biggest gainer on a day when LHAI announced concrete progress in monetizing its AI offerings. The company disclosed two linked developments: the commercial launch of its OpenLink decentralized AI compute platform and execution of a definitive enterprise contract worth up to US$10.5 million over two years. For a micro-cap or small-cap AI infrastructure play, securing an initial major customer contract with quantifiable near-term revenue represents exactly the kind of de-risking catalyst that drives outsized moves. The announcement came in two slightly overlapping headlines suggesting formal press releases, indicating this was a planned disclosure rather than speculation. The move reflects investor relief that the platform is now generating measurable enterprise demand rather than remaining in development or pilot stage.

BWET

Breakwave Tanker Shipping ETF

$257.35+$46.39

+22.0%

AMEX

No news headlines are available in the last 48 hours to explain the 21.99% gain in BWET. The move likely reflects a surge in tanker shipping rates or positive sentiment in the shipping sector, as the ETF is highly sensitive to spot rates and freight market conditions.

Despite no recent news headlines being available, the magnitude and rank of this move (21.99%, 19 biggest gainer) suggest a material catalyst. BWET is a shipping ETF that tracks tanker companies and their earnings, which are directly tied to daily freight rates and commodity shipping demand. The sharp gain most likely reflects either a notable spike in tanker spot rates driven by supply-demand dynamics (vessel availability, oil transport demand, geopolitical factors affecting shipping routes), or broader positive sentiment in the shipping sector. Without headlines, it is impossible to pinpoint a specific event, earnings announcement, or news driver. The move could also reflect technical buying pressure or a delayed reaction to previous news not yet indexed in the search results.

APACR

StoneBridge Acquisition II Corporation

$0.16+$0.03

+21.9%

OKTG

Leverage Shares 2x Long OKTA Daily ETF

$35.98+$6.45

+21.8%

NASDAQ

No news headlines were found in the past 48 hours, but OKTG's 21.84% gain is most likely driven by a sharp move in its underlying asset, Okta (OKTA), which this 2x leveraged daily ETF amplifies.

OKTG is a 2x leveraged daily ETF tracking Okta stock, so it is structurally designed to move roughly twice the daily percentage of its underlying. A +21.84% move in the ETF would correspond to approximately a +10-11% move in OKTA itself, which would be a substantial single-day gain for the security company. Without recent news headlines identified in the 48-hour window, the catalyst is not apparent from the provided information. However, the move is consistent with either positive earnings results, analyst upgrades, sector rotation into software/cybersecurity, or technical momentum in the underlying equity. Leverage ETFs are also sensitive to intraday volatility and can exhibit compounding effects that amplify intraday swings. Without confirmation of the underlying stock's move or any corporate announcement, the precise driver remains unknown.

LANV

Lanvin Group Holdings LimitedConsumer Cyclical

$1.47+$0.24

+19.5%

JSPR

Jasper Therapeutics, Inc.Healthcare

$0.72+$0.11

+18.9%

NASDAQ · Mkt cap $25 M

No news headlines were available in the last 48 hours, so the 18.9% intraday gain cannot be directly attributed to a reported event. The move is likely driven by technical factors, rumors, or delayed market reaction to earlier developments.

Jasper Therapeutics is a clinical-stage biopharmaceutical company with no earnings or revenue to support price moves on fundamentals, making it highly sensitive to sentiment, speculation, and technical trading. The absence of news in the 48-hour window before this 23rd-ranked gain suggests either a delayed market reaction to older news that did not appear in the Yahoo Finance RSS feed, accumulation driven by short-squeeze dynamics or retail interest, early-stage trial data leaking ahead of a formal announcement, or simply momentum trading in a micro-cap stock. Without a specific catalyst documented in the provided headlines, attribution remains speculative but the stock's clinical-stage status makes investor sentiment shifts and technical breakouts the most probable near-term movers.

RDAC

Rising Dragon Acquisition Corp.Financial Services

$6.30+$1.00

+18.9%

NASDAQ · Mkt cap $35 M

No headlines were found in the last 48 hours, so the 18.87% gain cannot be attributed to disclosed news. The spike is most likely driven by SPAC-related activity, technical momentum, or unreported developments.

Rising Dragon Acquisition Corp. is a SPAC, a structure that can experience sharp price moves on relatively thin volume when merger rumors surface, when deadline pressures force decisions, or when derivative positioning creates momentum. The absence of any news in the Yahoo Finance RSS feed over the past two days does not rule out material developments announced through other channels, regulatory filings, press releases outside major syndication, or social media discussion. SPACs in particular often trade on sentiment and timeline catalysts rather than fundamental news. Without access to SEC filings, company press releases, or social media chatter for the snapshot date, the specific trigger cannot be identified. The move ranks as the 24th biggest gainer, suggesting real volume and interest, but the cause remains opaque from the available evidence.

DYAI

Dyadic International, Inc.Healthcare

$1.21+$0.19

+18.6%

NASDAQ · Mkt cap $30 M

No news headlines were found in the last 48 hours, so the 18.63% gain on July 14 cannot be directly attributed to a specific announced event. The move was likely driven by technical factors, delayed news dissemination, or market rumors.

Dyadic International (DYAI) is a biotechnology company focused on enzyme and protein engineering, a sector that can experience sharp intraday moves on relatively low trading volume. With no headlines provided from the past 48 hours, the significant single-day gain cannot be traced to earnings, FDA decisions, partnership announcements, or guidance changes. In small-cap biotech stocks like this, price spikes of this magnitude often reflect technical factors such as short covering, option-related hedging adjustments, or delayed market reaction to news that may have circulated outside major RSS feeds. Alternatively, an announcement could have been made but not yet captured by the Yahoo Finance RSS feed used here. Without access to the company's investor relations channels or alternative news sources, attributing the move to a specific catalyst is not possible from the evidence provided.

BWEN

Broadwind, Inc.Industrials

$5.09+$0.79

+18.4%

NASDAQ · Mkt cap $115 M

No news headlines were available in the last 48 hours, so the 18.37% gain cannot be directly attributed to a reported catalyst. The move likely reflects technical momentum, short-covering, or an untracked announcement or rumor.

Broadwind is a mid-cap industrial equipment and services company with relatively low liquidity and a modest share price around five dollars, characteristics that can amplify intraday volatility. The absence of any news in the Yahoo Finance feed in the prior 48 hours means we cannot anchor the move to a specific event like earnings, contract wins, or guidance changes. However, stocks in this category often respond sharply to technical factors such as options expiration, short squeezes, or momentum trading in low-volume names. Alternatively, a material announcement—such as a new contract, strategic partnership, or operational update—may have been released but not yet indexed in the RSS feed or may have come after market close on the previous day. Without access to the company's investor relations announcements or intraday trading context, attributing the move to anything beyond generic technical or untracked catalyst categories is speculation.

BLSG

Leverage Shares 2x Long BLSH Daily ETF

$1.90+$0.29

+18.3%

NASDAQ

No news headlines were found in the last 48 hours, but BLSG is a 2x leveraged long ETF tracking BLSH, so an 18% gain likely reflects a strong ~9% move in the underlying stock or index, amplified by the fund's leverage structure.

The absence of headlines within the 48-hour window means no specific company announcement, earnings release, or sector catalyst can be attributed to this move based on the evidence provided. However, BLSG is a leveraged ETF product designed to deliver twice the daily return of its underlying index or benchmark. An 18% daily gain in BLSG would correspond to roughly a 9% underlying move in BLSH (before fees and rebalancing effects). This type of security typically responds to broad index rallies, sector rotations, or momentum shifts in the asset class it tracks rather than company-specific news. Without knowing what BLSH itself is or what drove it higher on July 14, 2026, the most likely causes are either a significant intraday rally in the underlying benchmark or a technical/sentiment-driven move in that segment.

NAKA

Nakamoto Inc.Financial Services

$3.98+$0.61

+18.1%

BTAI

BioXcel Therapeutics, Inc.Healthcare

$1.03+$0.15

+16.8%

NASDAQ · Mkt cap $26 M

No news headlines were found in the last 48 hours, so the 16.75% gain likely reflects a technical bounce, delayed market reaction to earlier news, or sector-specific movement in biotech equities.

BioXcel Therapeutics is a small-cap biotech company trading at $1.03, well below typical institutional investment thresholds. The absence of fresh headlines despite a significant one-day gain suggests the move was not triggered by breaking news. For a stock at this price and market cap, gains of this magnitude often reflect technical factors such as short covering or bounces off support levels, delayed reactions to news from prior weeks that may not yet be indexed in the Yahoo Finance feed, or participation in a broader biotech sector rally. Without access to the company's clinical pipeline status, regulatory calendar, or recent earnings history, it is not possible to identify a specific catalyst. The stock's low absolute price also makes it susceptible to retail or algorithmic trading activity that can produce outsized percentage moves on modest absolute volume.

CHRN

ChronoScale CorporationTechnology

$23.01+$3.29

+16.7%

NASDAQ · Mkt cap $2.9 B

No news headlines were found in the last 48 hours for CHRN, so the 16.68% gain lacks a documented catalyst. The move may reflect technical buying, delayed news, or market speculation unrelated to public announcements.

The absence of any Yahoo Finance headlines in the past two days makes it impossible to pinpoint a specific catalyst for ChronoScale's sharp 16.68% rally. This lack of public information suggests the move may be driven by factors outside the traditional news cycle. Possible explanations could include technical momentum or short covering, a delayed announcement not yet picked up by major news feeds, insider trading activity signaling an upcoming event, or sector-wide sentiment shifts. Without concrete evidence, assigning causation would be speculation. Investors should monitor for official company releases or upcoming earnings dates that might retroactively explain the move.

EAF

GrafTech International Ltd.Industrials

$6.62+$0.92

+16.1%

NYSE · Mkt cap $182 M

A market research report highlighting strong 10.5% CAGR growth forecasts for the ultra-high-purity graphite market through 2030, driven by EV battery and semiconductor demand, likely triggered the 16% gain in GrafTech as a major graphite supplier positioned to benefit from this secular trend.

The headline released this morning projects the ultra-high-purity graphite market will nearly double from $0.87 billion in 2025 to $1.43 billion by 2030, driven explicitly by lithium-ion battery anode demand and semiconductor expansion. GrafTech International is a leading producer of natural graphite products and serves precisely these end markets. While the headline does not announce a specific contract or internal company development, it provides third-party validation of a favorable multi-year demand thesis for the graphite sector. For a small-cap industrial commodity supplier, forward-looking market growth forecasts can serve as significant catalysts, especially if investors had underappreciated the strength of the EV and semiconductor tailwinds. The timing and specificity of the projection likely triggered algorithmic and momentum buying in the stock.

GALT

Galectin Therapeutics Inc.Healthcare

$5.34+$0.74

+16.1%

NASDAQ · Mkt cap $355 M

No news headlines were published in the last 48 hours for GALT, so the 16% gain likely reflects either a delayed market reaction to unreported news, technical trading, or sector momentum in biotech stocks.

The absence of any recent headlines in the 48-hour window creates a puzzle: a 16% single-day move in a small-cap biotech stock typically correlates with material corporate events such as clinical trial data, regulatory decisions, partnership announcements, or earnings surprises. Without access to news, we must consider alternative categories. Galectin Therapeutics focuses on fibrosis and oncology therapeutics, sectors where FDA decisions or Phase trial results can drive sharp repricing. The stock may have reacted to a press release or news event that has not yet appeared in the Yahoo Finance RSS feed used here, or it may reflect technical momentum, short covering, or sector-wide strength in biotech. Investor call activity or insider accumulation can also trigger moves before news becomes public, though this remains speculative.

ACTU

Actuate Therapeutics IncHealthcare

$1.73+$0.23

+15.3%

NASDAQ · Mkt cap $24 M

No news headlines were found in the last 48 hours, so the 15% gain in ACTU stock on July 14 likely reflects either a delayed market reaction to an earlier announcement, technical trading activity, or a catalyst not yet indexed by Yahoo Finance RSS.

The absence of any recent news headlines makes it difficult to pinpoint a specific catalyst for the 15.33% jump. Biotech and small-cap therapeutics stocks like Actuate can be sensitive to clinical trial results, FDA communications, partnership announcements, or shifts in investor sentiment around pipeline assets, but none of those events appear in the available news feed. It is also possible that the move reflects short covering, options-related buying pressure, or a delayed market reaction to news released before the 48-hour window. Without either a headline or structural knowledge specific to Actuate's current market position or shareholder base, we cannot reliably distinguish between these possibilities.

NUWE

Nuwellis, Inc.Healthcare

$3.22+$0.42

+15.0%

NASDAQ · Mkt cap $3.7 M

No news headlines were found in the last 48 hours, so the 15% gain likely reflects either a delayed market reaction to an earlier announcement, technical trading activity, or sector-wide momentum in medical device stocks.

Nuwellis is a medical device company focused on ultrafiltration and fluid management solutions. The absence of any recent headlines in the 48-hour window means the jump cannot be attributed to earnings, FDA clearances, partnership announcements, or other typical catalyst events visible in public news feeds. For a stock ranked 34th among daily gainers with a move of this magnitude, the cause could fall into several categories: a press release issued outside major news aggregators, short covering or technical bounce after prior weakness, positive commentary from an analyst or insider, broader sector rotation into healthcare or medical devices, or simply elevated retail trading interest. Without corroborating news, any specific explanation remains speculative. The stock's relatively low price point around $3.22 also makes it susceptible to outsized percentage moves from smaller absolute dollar volume shifts.

KORU

Direxion Daily MSCI South Korea Bull 3X ETF

$481.34+$62.15

+14.8%

AMEX

No news headlines were found in the last 48 hours, but KORU's 14.83% gain is most likely driven by a broad rally in South Korean equities or markets, amplified by the fund's 3x daily leverage.

KORU is a leveraged inverse-tracking ETF that aims for 3x daily returns of the MSCI South Korea index. Without news headlines directly tied to the move, the most probable explanation is a significant rally in the underlying South Korean stock market or broader risk-on sentiment that lifted Asian equities on July 14, 2026. Because KORU uses daily 3x leverage, even a modest 5% jump in the MSCI South Korea index would produce roughly a 15% move in the ETF, which aligns with the observed price action. Other possibilities include a delayed market reaction to earnings from major South Korean firms, geopolitical de-escalation, or changes in macro conditions such as interest rate expectations, but these remain inference rather than established fact from the provided data.

ALP

Alpha Compute CorpFinancial Services

$0.33+$0.04

+14.5%

NASDAQ · Mkt cap $4.1 M

No news headlines were found in the last 48 hours to explain ALP's 14.51% gain, so the catalyst remains unclear; the move could reflect technical trading, delayed news dissemination, or sector momentum in compute stocks.

The absence of any news in the Yahoo Finance RSS feed over the last 48 hours means we cannot point to a specific corporate event, earnings surprise, product announcement, or industry development as the driver of this gain. ALP is ranked 36th among daily gainers, so it experienced a material move despite no identified headline catalyst. In such cases, moves in small-cap or micro-cap tech stocks like Alpha Compute Corp often reflect technical factors such as short covering, algorithmic buying into oversold conditions, or sector-wide momentum in AI and compute-related shares. Alternatively, news may have circulated through non-RSS channels or may not yet be indexed. Without access to insider activity, social media chatter, or trading volume data, attributing the gain to any specific mechanism remains speculative.

SHLS

Shoals Technologies Group, Inc.Technology

$10.76+$1.36

+14.5%

NASDAQ · Mkt cap $1.2 B

No headlines were found in the last 48 hours explaining SHLS's 14.47% gain, so the catalyst remains unclear; the move may reflect technical positioning, delayed news flow, or sector momentum in renewable energy stocks.

Despite Shoals Technologies being a provider of electrical balance-of-system solutions for solar and battery storage installations, no news headlines were available in the Yahoo Finance RSS feed for the 48 hours preceding this snapshot. The stock ranks 37th among daily gainers, suggesting material buying interest, but without corresponding news coverage it is difficult to pinpoint a specific catalyst. Shoals is exposed to the renewable energy and solar installation sector, which can experience momentum-driven rallies or respond to policy announcements, broader market sentiment shifts, or company-specific developments that take time to reach headline distribution. Additionally, smaller-cap or specialized industrial stocks sometimes experience sharp moves on light trading volume or technical factors that precede broader news dissemination.

DLLL

GraniteShares 2x Long DELL Daily ETF

$27.46+$3.42

+14.2%

NASDAQ

No news headlines are available from the past 48 hours, but DLLL surged 14.23% as a 2x leveraged long ETF on Dell, likely reflecting a substantial rally in the underlying DELL stock or broader tech sector strength.

Yahoo Finance returned no headlines for DLLL in the last 48 hours, so we cannot point to a specific corporate event or news catalyst. However, DLLL is a leveraged ETF designed to deliver twice the daily return of Dell Technologies stock. A 14.23% gain in DLLL would imply approximately a 7% move in the underlying DELL stock on the day. The most probable explanations are a significant single-day rally in Dell driven by earnings results, analyst upgrades, or positive guidance; broad-based tech sector strength; or short-covering in a thinly leveraged product. Without headlines confirming Dell-specific news, we cannot rule out algorithmic momentum or intraday technical factors typical of leveraged instruments.

BNZI

Banzai International, Inc.Technology

$2.74+$0.34

+14.2%

NASDAQ · Mkt cap $5.6 M

Banzai International announced the closing of a $0.9 million underwritten public offering on July 14, which likely triggered the 14% gain as market participants reacted positively to the capital raise and company news flow.

The stock jumped 14.17% on the same day Banzai announced the closing of its $0.9 million underwritten public offering, following the pricing announcement on July 13. The timing and proximity of the news to the price move suggest a direct causal link. However, the modest size of the offering and the lack of detail in the headline excerpts prevent a more granular assessment. Typically, capital raises generate mixed reactions depending on dilution concerns, use of proceeds, and market conditions. The positive move here suggests investors either welcomed the cash infusion, viewed it as de-risking the company, or the announcement simply drew attention to a smaller-cap stock that may have been undertraded. Without information on share count impact or capital deployment plans, the precise mechanism of the gain remains partially opaque.

GCTK

GlucoTrack, Inc.Healthcare

$0.53+$0.07

+14.1%

NASDAQ · Mkt cap $3.7 M

GlucoTrack completed a strategic business combination with Lōkahi Therapeutics on July 14th, creating a combined public platform with access to Lōkahi's AI-driven drug development capabilities, which likely drove the 14% gain as investors priced in the merger upside.

The news headline directly announces the completion of a strategic business combination between GlucoTrack and Lōkahi Therapeutics, effective on the same day as the stock's 14% rally. The combination positions the merged entity to leverage public market access alongside Lōkahi's proprietary ai²-driven asset sourcing and development platform, which represents a material strategic enhancement. M&A announcements, particularly those framed as capital-efficient with synergistic platform advantages, typically drive positive initial market reactions as investors anticipate value creation and competitive positioning improvements. The timing alignment between the completion date and the stock's significant gain strongly suggests this event was the primary catalyst. However, the headline text is truncated and lacks detail on valuation, share structure changes, or specific financial terms that could provide fuller context.

YXT

YXT.COM Group Holding LimitedTechnology

$3.88+$0.48

+14.1%

NASDAQ · Mkt cap $19 M

No news headlines were found in the last 48 hours, so the 14.12% gain on YXT likely reflects technical trading, delayed news pickup, or market sentiment shifts unrelated to major corporate announcements.

YXT.COM Group Holding Limited jumped 14.12% to rank as the 41st biggest gainer on the day, but no recent news headlines are available to explain the move. This absence of news coverage is notable for a stock making a top-50 move. The gain could reflect several categories of catalyst: technical bounce from oversold conditions, accumulation by insiders or larger holders, short covering if the stock has a meaningful short float, or delayed market reaction to news not yet picked up by Yahoo Finance RSS feeds. For smaller-cap Chinese listings like YXT, information asymmetries are common, and moves can occur on rumors or private sentiment before public confirmation. Without specific headlines linking the move to earnings, guidance, partnerships, or restructuring, we cannot pinpoint a single cause.

AXTI

AXT, Inc.Technology

$57.57+$7.11

+14.1%

NASDAQ · Mkt cap $3.7 B

After falling 11.80% on July 13 amid negative investor sentiment and export delay concerns, AXTI surged 14.09% on July 14, likely driven by a rebound in confidence around its strong InP backlog, AI optical demand tailwinds, and multi-year capacity expansion announced on July 13.

The headlines reveal a classic pattern of sell-then-bounce momentum. On July 13, AXTI fell sharply as investors fled ahead of earnings concerns and amid broader export delays and cash-flow risks. However, the same day AXT announced an aggressive InP capacity ramp through 2028, citing a $100M-plus backlog and Tier-1 customer adoption driven by AI optical demand. The July 14 surge appears to be a correction as investors reassessed the strength of the underlying demand fundamentals. The technical bounce off the 50-day SMA combined with the constructive guidance on multi-year growth likely attracted buyers who had panicked on July 13. This is a sector-sensitive play where AI momentum narratives can drive sharp intraday reversals.

ATAI

Atai Beckley Inc.Healthcare

$5.67+$0.70

+14.1%

NASDAQ · Mkt cap $2.7 B

ATAI surged 14% likely driven by positive FDA guidance on psychedelic drug development and renewed industry enthusiasm for psychedelic therapeutics, as reflected in multiple supportive headlines on the same day.

Three headlines dropped on or within 48 hours of the move, all supportive of ATAI's business. Most directly relevant is the July 13 Jefferies report noting that finalized FDA guidance on psychedelic drug development signals receptiveness to developers including AtaiBeckley, removing regulatory uncertainty that has historically weighed on the sector. The July 14 WSJ piece highlighting intense pharmaceutical interest in psychedelic therapeutics (specifically toad-derived compounds) provides broader sector tailwinds. A July 14 performance comparison article, while less directly bullish, keeps ATAI in the conversation as a sector leader. The combination of clearer regulatory pathways and demonstrated pharma capital flowing into psychedelics likely encouraged investors to reassess risk around ATAI's pipeline and commercialization prospects.

ZCMD

Zhongchao Inc.Healthcare

$1.72+$0.21

+13.9%

NASDAQ · Mkt cap $6.2 M

No news headlines were found in the last 48 hours for ZCMD, so the 13.91% gain on July 14 cannot be directly attributed to a disclosed catalyst. The move likely reflects technical or market-driven factors common to low-priced stocks.

The absence of any recent news in Yahoo Finance's RSS feed means we cannot ground the intraday jump in a specific corporate announcement, earnings release, regulatory action, or strategic event. ZCMD trades at $1.72, placing it in the micro-cap territory where price moves can be amplified by low liquidity, short-covering, retail trading momentum, or simply technical rebound after prior weakness. Without access to intraday volume data, insider filings, or after-hours news from other sources, we cannot determine whether this was driven by a delayed earnings report, a press release issued outside standard newswires, speculative positioning, or broad market sector rotation. The lack of disclosed information leaves multiple hypotheses open.

SEZL

Sezzle Inc.Financial Services

$182.39+$22.14

+13.8%

NASDAQ · Mkt cap $3.8 B

Sezzle announced it will release Q2 2026 results and participate in investor conferences, likely sparking optimism ahead of the earnings report and increased investor visibility.

The headline confirms that Sezzle will announce second quarter 2026 results after market close on an unspecified date and participate in upcoming investor conferences. This type of announcement typically generates positive sentiment for a few structural reasons: forward visibility into earnings calls can attract conference participants and media attention, and companies often time such announcements strategically when they expect favorable results. The 13.82% single-day gain is substantial but not unprecedented for fintech stocks ahead of earnings, particularly if investors had been positioned negatively or if the stock had underperformed recently. However, the headline itself contains no actual earnings data, guidance revision, or specific catalyst beyond the scheduling announcement. The move could reflect either genuine earnings optimism or technical momentum in a stock that may have been oversold. Without the actual Q2 results or any forward guidance embedded in this release, we cannot confirm whether fundamentals drove the move or if it is sentiment-based.

PANG

Leverage Shares 2x Long PANW Daily ETF

$33.52+$4.06

+13.8%

NASDAQ

No news headlines were found in the last 48 hours, but PANG is a 2x leveraged long ETF tracking Palo Alto Networks, so a 13.77% gain likely reflects a significant rally in the underlying PANW stock amplified by the fund's leverage structure.

The absence of recent headlines makes it impossible to identify a specific catalyst from news sources. However, PANG's structure as a 2x daily leveraged long ETF means it amplifies moves in Palo Alto Networks (PANW) by approximately double on a daily basis. A 13.77% gain in PANG would correspond to roughly a 6-7% move in the underlying stock. This magnitude of move in PANW could stem from several typical catalysts: a positive earnings surprise or guidance raise, a major enterprise deal announcement, upgraded analyst ratings, broader cybersecurity sector strength, or positive macro sentiment toward software stocks. Without access to real-time PANW price data or additional news sources beyond the Yahoo Finance RSS feed provided, the specific driver cannot be determined. The timing of the jump and strength suggest a substantive market event rather than routine trading noise.

PRE

Prenetics Global LimitedConsumer Defensive

$21.24+$2.56

+13.7%

NASDAQ · Mkt cap $315 M

Prenetics' IM8 supplement brand secured $1 billion in growth financing from General Catalyst on July 14, driving the 13.70% intraday jump despite a broader healthcare sector decline.

The headline directly attributes a major capital raise to IM8, Prenetics' premium supplement subsidiary, which the company describes as the fastest-growing brand in its category with 200,000 servings delivered daily and 50 million cumulative servings to date. A billion-dollar growth investment from a tier-one venture capital firm signals strong validation of the business model and provides substantial runway for scaling. The timing of the news release on market close (17:35 UTC) aligns with the stock's significant gain. The fact that PRE moved +13.70% while the broader healthcare sector fell 1.7% late in the session suggests the market viewed this financing as company-specific good news that outweighed sector headwinds. No earnings, FDA decisions, or other operational metrics were disclosed in the available headlines.

PALU

Direxion Daily PANW Bull 2X ETF

$54.32+$6.53

+13.7%

AIRO

AIRO Group Holdings, Inc. Common StockIndustrials

$6.87+$0.82

+13.6%

NASDAQ · Mkt cap $271 M

AIRO's RQ-35 Heidrun ISR drone was added to the U.S. Blue UAS list on July 14, which likely triggered the 13.55% gain as this regulatory approval opens military procurement pathways for the company's key defense product.

The headline announces that AIRO's RQ-35 Heidrun drone has been added to the U.S. Blue UAS (Unmanned Aircraft Systems) list. This is a meaningful development for a defense contractor because the Blue UAS list represents approved platforms for U.S. military and federal government use, removing a critical barrier to large-scale procurement. For a company whose primary business appears to center on drone technology for military and intelligence applications, regulatory approval of this magnitude typically signals expanded addressable market and de-risked sales pathways. The timing of the announcement on market open and the stock's rank among top gainers suggests the market is pricing in meaningful upside from this certification. However, the headline does not specify contract value, timeline to revenue, or competitive context that would fully justify the magnitude of the move.

TGB

Trekor Metals LimitedBasic Materials

$7.97+$0.95

+13.5%

AMEX · Mkt cap $3.1 B

Trekor Metals reported strong second-quarter copper production of 36 million pounds across its Gibraltar and Florence Copper operations on July 14, driving a 13.53% gain in TGB stock as a top-50 daily mover.

The company announced Q2 copper cathode production totaling 36 million pounds, with Gibraltar mine alone contributing 30.3 million pounds. This production report appears to have met or exceeded market expectations for a major copper producer, triggering the substantial intraday rally. For commodity producers like Trekor Metals, quarterly production figures are key operational metrics that investors monitor closely, as they signal operational efficiency, mine performance, and cash generation capacity. The timing of the announcement on market hours (12:30 UTC) followed by confirmation reporting (16:30 UTC) aligns with the stock's strong upward movement. No negative guidance revisions or operational issues are mentioned, suggesting the market received the production data positively relative to prior consensus or concerns.

Biggest Losers

Tue, Jul 14, 2026 50

LCDL

GraniteShares 2x Long LCID Daily ETF

$0.29−$0.30

-51.3%

NASDAQ

No news headlines were found in the last 48 hours, but the -51.25% crash is likely driven by a sharp drop in the underlying Lucid stock (LCID), which this 2x leveraged daily ETF amplifies mechanically.

LCDL is a 2x long leveraged daily ETF tracking Lucid Automotive (LCID). Because it uses daily reset mechanics and 2x leverage, it amplifies both gains and losses in the underlying stock. A -26% move in LCID would produce roughly a -51% move in LCDL, which matches today's observed decline almost exactly. No news headlines were surfaced for the past 48 hours, so the catalyst affecting LCID remains unclear from the data provided. Possible drivers could include earnings disappointment, guidance cuts, industry-wide EV headwinds, analyst downgrades, or technical selling, but without specific headlines or LCID price action data, the exact cause cannot be determined. The fact that LCDL experienced the single largest one-day loss suggests significant selling pressure on the underlying stock.

LESL

Leslie's, Inc.Consumer Cyclical

$3.30−$2.30

-41.1%

NASDAQ · Mkt cap $6.1 M

Leslie's stock crashed 41% on July 14 with no news headlines available in the prior 48 hours, making the immediate cause unclear but suggesting either a delayed earnings miss, margin guidance cut, or unannounced material event not yet reflected in RSS feeds.

No recent headlines in the Yahoo Finance RSS feed explain the 41% single-day collapse for LESL. Leslie's is a pool and spa supplies retailer highly sensitive to consumer spending and seasonal demand cycles. A drop of this magnitude typically reflects either earnings disappointment (weak pool chemical sales or margin compression), negative guidance revision, debt covenant concerns, or sector-wide retail weakness. Given the stock is ranked the second-biggest loser of the day, this appears to be a fundamental event rather than pure technical selling. The absence of any RSS coverage within 48 hours suggests either the news broke very recently (perhaps after market open or after RSS aggregators updated), or the catalyst is still trickling out. Deteriorating pool season demand, supply chain issues, or a surprise CEO departure would fit this stock's historical volatility profile.

STAK

STAK Inc. Ordinary SharesEnergy

$2.23−$1.50

-40.1%

NASDAQ · Mkt cap $29 M

STAK dropped 40% with no news headlines in the last 48 hours, making the precise trigger unknown; the move likely reflects a major corporate event, earnings release, or market-moving announcement that occurred outside the captured news window.

No headlines were found in the last 48 hours to directly explain this severe 40% single-day decline. A move of this magnitude typically requires a significant catalyst such as earnings that missed consensus, a guidance cut, material litigation news, a failed clinical trial or regulatory setback, executive departure, debt covenant issues, or acquisition-related developments. Because the news feed is empty while the stock ranks third-worst for the day, the triggering event either occurred before the 48-hour window, was not yet indexed by the news source, or broke after market close on the prior trading day. Without access to the company's news releases, SEC filings, or broader market commentary, attributing causality would be speculation.

FTRK

Fast Track GroupCommunication Services

$0.43−$0.16

-27.5%

NASDAQ · Mkt cap $3.0 M

FTRK fell 27.5% on July 14, 2026, with no news headlines available in the prior 48 hours to explain the decline. The cause remains unclear without additional information.

Fast Track Group experienced a significant single-day drop of 27.5% to $0.43 per share, ranking it among the day's biggest losers. However, no news articles were found in the last 48 hours on Yahoo Finance to account for this move. At this price level and given the magnitude of decline, potential catalysts could include: deterioration in an unreported earnings miss or guidance cut that may have been announced through a press release not yet syndicated to RSS feeds; a shareholder announcement, reverse split filing, or dilutive capital raise; a short seller report or negative commentary from an analyst; or technical factors such as liquidation pressure or options-related activity. Without corroborating headlines, it is impossible to identify which category applies or whether the move reflects company-specific news versus broader market mechanics affecting the stock.

MTNB

Matinas BioPharma Holdings, Inc.Healthcare

$0.35−$0.13

-27.1%

AMEX · Mkt cap $1.3 M

Matinas announced a transformative business combination with GH Power (shifting the company from biopharmaceuticals to clean energy) and the simultaneous sale of its core LNC platform and lead drug candidate to Azurity, which likely triggered a sharp selloff from existing shareholders who held th…

The two announcements published on July 13 constitute a fundamental pivot for Matinas BioPharma. The company is exiting the pharmaceutical business by selling its LNC technology platform and lead drug MAT2203 to Azurity Pharmaceuticals, while simultaneously agreeing to merge with GH Power, a clean energy and green hydrogen company. This represents a near-complete business model change: investors who bought Matinas as a biopharmaceutical play are seeing the clinical-stage drug pipeline liquidated and the company reborn as an energy infrastructure company. The -27% drop reflects likely disappointment among existing shareholders who either disagreed with the strategic direction, questioned the valuation of the deal, doubted management's ability to execute in a new sector, or simply lost confidence in the combined entity's prospects. The sale of core assets at potentially unfavorable terms may have also signaled distress.

UBXG

U-BX Technology Ltd.Communication Services

$4.61−$1.69

-26.8%

NASDAQ · Mkt cap $11 M

No news headlines were found in the last 48 hours, so the 26.83% drop likely stems from a delayed market reaction, technical breakdown, sector weakness, or undisclosed company event that has not yet appeared in major financial media.

The absence of any news in the Yahoo Finance RSS feed over the past 48 hours means we cannot point to a specific catalyst such as earnings, guidance, regulatory action, or corporate announcement. A single-day loss of over 26 percent for a micro-cap stock like UBXG (trading at $4.61) typically reflects either a significant material event that has not yet been widely reported, a sharp technical breakdown following prior weakness, a sector-wide selloff affecting comparable companies, or potentially a delayed disclosure of insider information or adverse developments. Without access to real-time market data, trading volume, or other contemporaneous news sources beyond the provided RSS, determining the actual trigger is speculative. Micro-cap stocks are particularly prone to large intraday swings driven by illiquidity, short covering, or sudden shifts in investor sentiment.

RGNT

Regentis Biomaterials Ltd.Healthcare

$2.54−$0.93

-26.8%

AMEX · Mkt cap $16 M

No news headlines were found in the last 48 hours, so the 26.80% drop cannot be attributed to a specific announced event. The decline likely reflects either broader market weakness, a delayed news catalyst, or technical selling pressure in this small-cap biotech stock.

Regentis Biomaterials is a small-cap biotech company, and the absence of recent news makes it difficult to pinpoint a single cause for the sharp 26.80% decline on July 14, 2026. Stocks in this sector are typically sensitive to clinical trial results, regulatory decisions, funding announcements, partnership updates, or shifts in investor sentiment toward biotech risk. The magnitude of the drop suggests something material occurred, but without headline evidence it could represent reaction to a delayed announcement, internal company news not yet picked up by major news feeds, broader biotech sector weakness, or a technical breakdown in a stock with likely thin trading volume. Small biotech names are also prone to momentum-driven reversals and short-covering dynamics that can amplify single-day moves.

IBM

International Business Machines CorporationTechnology

$217.07−$73.16

-25.2%

NYSE · Mkt cap $221 B

IBM issued a disappointing preliminary second-quarter earnings warning on July 14, citing customer spending shifts toward AI hardware and away from software, causing a 25% single-day plunge, the stock's worst day ever.

The headlines establish a concrete earnings warning from IBM released on July 14. CEO Arvind Krishna attributed the Q2 miss to enterprise customers reallocating budgets away from software toward memory chips and AI hardware purchases, anticipating higher semiconductor prices. This spending shift had cascading effects: software companies including Adobe, ServiceNow, Workday, HubSpot, Asana and Appian also fell as investors inferred similar pressure on their revenue. The timing coincided with a cooler-than-expected inflation report and a Morgan Stanley reiteration on Nvidia, which boosted semiconductor stocks like MACOM and Lattice Semiconductor. IBM's earnings warning also triggered concern about dividend sustainability. The 25% one-day drop reflects not only the specific Q2 miss but market repricing of IBM's competitive position in an AI-accelerated enterprise environment where hardware purchasing dominates software spending.

PSQH

PSQ Holdings, Inc.Technology

$3.64−$1.18

-24.5%

NYSE

PSQH dropped 24.48% on July 14, 2026, but no news headlines were found in the last 48 hours, making the direct cause unclear without additional context.

The absence of any Yahoo Finance headlines in the prior 48 hours means we cannot point to a specific earnings report, regulatory action, product announcement, or guidance change as the catalyst. A 24.48% single-day decline is substantial and typically driven by material corporate news, sector-wide turmoil, or a significant technical event. For a company like PSQH (a financial services/mortgage fintech firm based on its ticker profile), possible explanations could include a delayed earnings miss or guidance slash that has not yet surfaced in headline feeds, negative broker downgrade circulating before formal publication, broader market stress in financial services or mortgage lending, or a technical sell-off triggered by stop-loss orders. Without headline confirmation, we cannot distinguish among these or rule out other catalysts entirely.

XAIR

Beyond Air, Inc.Healthcare

$5.77−$1.72

-23.0%

NASDAQ · Mkt cap $5.1 M

Beyond Air (XAIR) dropped 22.96% on July 14, 2026, but no news headlines were found in the last 48 hours, making the specific catalyst unclear from public information sources.

The absence of any recent news headlines in the provided data makes it impossible to pinpoint a definitive cause for the sharp 22.96% decline. Beyond Air is a small-cap medical device company focused on inhaled nitric oxide therapies, and stocks in this category typically respond to clinical trial results, FDA decisions, partnership announcements, or changes in cash position and funding outlook. Given the magnitude of the move, the catalyst was likely material—possibilities include negative clinical or regulatory developments, an unexpected financing at a dilutive price, insider selling, analyst downgrades, or technical selling pressure following a failed support level. Without access to news sources beyond the Yahoo Finance RSS feed provided, the actual trigger remains speculative.

DFNS

T3 Defense Inc.Industrials

$0.07−$0.02

-22.3%

NASDAQ · Mkt cap $27 M

DFNS fell 22.28% despite positive news of a $1.1 million defense contract delivery, suggesting the market reaction was driven by factors unrelated to the headline announcement or broader sector headwinds.

The single headline from the past 48 hours reports that T3 Defense's subsidiary Rimon successfully delivered a $1.1 million order to a major Israeli defense customer for advanced battlefield lighting systems. This is conventionally positive news—concrete revenue, named customer, growing demand narrative. Yet the stock dropped sharply, ranking as the 11th biggest loser of the day. This disconnect suggests either the market has concerns that outweigh the contract win (balance sheet stress, dilution announcement, guidance warning, or competitive threat embedded elsewhere), or the decline stems from technical factors, short covering, broader market selloff in micro-cap defense stocks, or delayed negative news not yet captured in the RSS feed. The stock's penny-stock price level ($0.07) also indicates high volatility and low liquidity, where single large trades can create outsized moves independent of fundamentals. Without access to full press releases, earnings context, or concurrent company announcements, the true catalyst remains unclear.

ZSQR

Coeptis Therapeutics Holdings, Inc.Technology

$5.60−$1.60

-22.2%

NASDAQ · Mkt cap $218 M

No news headlines were available in the last 48 hours to explain the 22% drop, so the cause remains unclear; biotech stocks often fall on clinical trial setbacks, regulatory rejection, or funding concerns that may not have been immediately reported.

Coeptis Therapeutics is a clinical-stage biotech company, and a 22% single-day decline without accompanying news in the headline feed is unusual but not unprecedented for this sector. Possible catalysts include a clinical trial result or safety event that was announced but not yet indexed by Yahoo Finance, regulatory feedback or rejection of a development program, unexpected dilution from a financing, or a leaked negative development that spreads before formal disclosure. Biotech equities are particularly sensitive to binary clinical and regulatory outcomes. Without the specific news, we cannot rule out technical selling, short covering reversal, or delayed market reaction to information released outside standard news channels. The absence of reported headlines is itself notable and suggests either the catalyst has not yet been formally announced or the move may be driven by intraday trading dynamics rather than fundamental news.

SPRO

Spero Therapeutics, Inc.Healthcare

$1.70−$0.48

-22.0%

NASDAQ · Mkt cap $72 M

Spero announced a $105 million royalty financing deal and in-licensed a Phase 2 immunology candidate on the same day, yet the stock fell 22%, suggesting the market viewed the financing terms or dilution risk as value-destructive despite the positive news developments.

The headlines reveal three major positive announcements released within minutes of each other on July 14: a $105 million non-dilutive royalty financing with Healthcare Royalty/KKR, an exclusive global license for SP001 (a Phase 2-ready anti-CD40L antibody from Innovent Biologics), and deal details on milestones and royalties tied to Utebzi. These are typically bullish catalysts. However, the 22% decline suggests the market either interpreted the financing terms as unfavorable (perhaps the royalty structure or timeline creates long-term shareholder dilution), viewed the in-license fee or milestone obligations as onerous relative to SP001's pipeline value, or had negative expectations about deal economics that weren't immediately disclosed. The stock's biotech peer dynamics and risk sentiment on early-stage immunology candidates may also have weighed on sentiment despite the capital infusion.

FIEE

FiEE, Inc.Technology

$3.25−$0.89

-21.5%

NASDAQ · Mkt cap $40 M

FIEE dropped 21.5% on July 14, 2026, but no news headlines were available in the prior 48 hours, so the specific catalyst remains unclear. The move may reflect a delayed market reaction to an untracked announcement, a technical breakdown, or broader sector pressure.

No headlines from Yahoo Finance RSS in the last 48 hours provide direct explanation for FIEE's sharp 21.5% decline. This absence of reported news creates ambiguity about the immediate trigger. The stock's position as the 14th biggest loser suggests material movement rather than random noise. Possible causes include a company announcement released outside major wire services, a product recall or regulatory setback not yet widely indexed, institutional fund rebalancing, short-seller activity disclosure, or contagion from a broader market or sector event. Without news confirmation, any explanation remains speculative. Small-cap stocks like FIEE sometimes experience price swings on low liquidity combined with technical chart breaks, making it difficult to pinpoint a fundamental cause without additional context.

YAAS

Youxin Technology LtdTechnology

$0.74−$0.19

-20.7%

NASDAQ · Mkt cap $45 M

No news headlines were found in the last 48 hours for YAAS, so the 20.74% drop cannot be directly attributed to a specific announced event. The decline is likely driven by technical selling, sector rotation, or untracked developments.

The absence of any recent news in the provided search results means we cannot point to a specific catalyst such as earnings, a regulatory decision, or corporate announcement. For a microcap NASDAQ-listed stock like Youxin Technology trading at $0.74, sharp intraday moves are not uncommon and can be triggered by several categories of events: thin liquidity and technical support breaks, short-covering or momentum unwinding, sector-wide weakness in technology or China-focused equities, delayed or informal news not yet indexed by major financial feeds, or shifts in sentiment among retail traders. Without access to the actual headlines or the stock's technical chart, we cannot distinguish between these possibilities. The rank as the 15th biggest loser suggests broader market pressure that day, but Youxin's particular exposure or sector remains unclear from the data provided.

GMEX

GMEX ROBOTICS CORPORATION Class ATechnology

$1.50−$0.37

-19.8%

NASDAQ · Mkt cap $1.0 M

GMEX Robotics announced a non-binding letter of intent for an AI platform acquisition today, but the market reacted with a 19.79% sell-off, suggesting investor skepticism about the deal's strategic value or concern over execution risk and capital allocation.

The company issued two press releases on July 14 announcing a letter of intent to acquire an AI platform specializing in social intelligence and human behavioral modeling. On the surface this appears to be a strategic growth move to enhance GMEX's AI and robotics capabilities. However, the sharp sell-off on the announcement day indicates the market viewed the deal negatively. Possible explanations include concerns about acquisition pricing and shareholder dilution, doubt about synergy realization, worry that management is chasing AI trends without clear ROI, or skepticism about the target company's technology or market relevance. The non-binding nature of the LOI may also signal uncertainty. Without details on deal structure, valuation, or financing terms in the headlines, the market's negative reaction suggests underlying skepticism rather than enthusiasm for the proposed acquisition.

JZXN

Jiuzi Holdings, Inc.Consumer Cyclical

$1.23−$0.28

-18.5%

NASDAQ · Mkt cap $687 K

No news headlines were found in the last 48 hours, so the 18.54% decline cannot be directly attributed to a specific announced event; the drop likely reflects broader market sentiment, technical selling, or a delayed company announcement not yet indexed by the news feed.

The absence of news in the 48-hour window preceding this significant single-day decline is notable and limits the ability to pinpoint a specific catalyst. For a microcap stock like Jiuzi Holdings trading at $1.23, declines of this magnitude can result from several common drivers: earnings misses or disappointing guidance released outside the news feed window, short-seller reports or social media campaigns questioning the company's business model or financials, technical breakdown through support levels triggering stop-loss cascades, or delayed reactions to previously announced but initially overlooked bad news. Without headline evidence, any attribution remains speculative. The rank as the 17th biggest loser of the day suggests this was a market-wide trading day with multiple large-cap names also declining, which could indicate either a sector-specific downturn in the stock's industry or a broader market pullback rather than company-specific news.

FBYD

Falcon's Beyond Global, Inc. Class A Common StockIndustrials

$10.72−$2.35

-18.0%

NASDAQ · Mkt cap $387 M

No news headlines were available in the last 48 hours, so the 17.98% drop cannot be directly attributed to a specific announced event. The decline likely stems from broader market sentiment, technical selling, or undisclosed company developments.

The absence of any recent news headlines makes it impossible to pinpoint a concrete cause for Falcon's Beyond Global's sharp 17.98% decline. Falcon's Beyond is an experiential entertainment and theme park company, the type that can be sensitive to consumer spending outlook, operational updates, or guidance revisions. Without access to earnings releases, management commentary, industry developments, or market-wide selloffs that might have affected the stock, the most probable categories of catalyst would be either an unannounced earnings miss or guidance cut from the company itself, a broader pullback in discretionary consumer or entertainment equities, or a technical break below a key support level triggering algorithmic selling. The stock's rank as the 18th biggest loser of the day suggests the move was meaningful enough to be sector-leading or stock-specific rather than part of a broad market decline.

MIMI

Mint Incorporation LimitedIndustrials

$2.44−$0.52

-17.6%

NASDAQ · Mkt cap $14 M

No news headlines were found in the last 48 hours for MIMI, so the 17.57% decline cannot be attributed to a specific announced catalyst. The drop likely reflects either technical selling pressure, delayed reaction to an earlier announcement, or market-specific factors not captured in available ne…

The absence of recent headlines creates a genuine information gap. A near-18% single-day loss is material and suggests either a significant event that has not yet propagated to major news feeds, a technical breakdown in the stock's price action, or a delayed market reaction to information released earlier than the 48-hour window. Smaller-cap NASDAQ stocks like MIMI can be sensitive to momentum shifts, short-covering reversals, or sector-specific headwinds that may precede formal news announcements. Without access to company filings, SEC announcements, or social media signals beyond the provided headlines, attributing this move to a specific catalyst would be speculation. The rank as the 19th biggest loser suggests broad market participation in the sell-off rather than a single stock-specific negative event, though that remains inference without supporting evidence.

EDBL

Edible Garden AG IncorporatedConsumer Defensive

$3.48−$0.72

-17.1%

NASDAQ · Mkt cap $1.8 M

Edible Garden announced a successful prototype milestone on the same day the stock fell 17%, suggesting the positive development announcement either failed to meet investor expectations or was overshadowed by unrelated negative catalysts not captured in the headlines provided.

The only news available is a July 14 announcement that Edible Garden completed a clean-label ready-to-drink prototype at Tetra Pak's facility, described as advancing their Farm-to-Formula platform and accelerating commercialization. This appears to be a positive operational milestone. However, the stock dropped sharply the same day, ranking among the top 20 losers. This disconnect between headline positivity and price action suggests either the market viewed the announcement as insufficient or underwhelming relative to expectations, or more likely that a separate negative catalyst not reflected in the provided news headlines drove the decline. Possible drivers could include broader market conditions, company guidance revisions, insider selling, analyst downgrades, or sector-specific headwinds that were not captured by the news feed available.

AGEN

Agenus Inc.Healthcare

$5.08−$1.04

-17.0%

NASDAQ · Mkt cap $329 M

Agenus fell 16.99% despite positive clinical data and a $340M financing announcement on July 13-14, suggesting market disappointment with the terms, dilution from the private placement, or warrant dilution concerns offsetting the positive news.

The stock surged sharply on July 13-14 following announcement of up to $340M in financing and positive Phase 1b data for its botensilimab plus balstilimab combination in colorectal cancer, with reports of 74-100% gains. However, the stock reversed sharply into today's close, ending down 16.99% despite these headlines. The most likely explanation is that investors initially priced in the positive clinical data and financing availability, but then reassessed the dilution impact of the private placement itself (initial $85M tranche plus up to $255M more) or the warrant exercise provisions. Biotech investors often sell into strength on capital raises due to shareholder dilution concerns, even when the capital supports promising trials. The pivot away from the BATTMAN study may also have disappointed some investors betting on that program.

ICG

Intchains Group LimitedTechnology

$0.83−$0.17

-17.0%

NASDAQ · Mkt cap $53 M

No news headlines were found in the last 48 hours, so the 16.99% drop on July 14, 2026 cannot be directly attributed to a specific company announcement or market event based on available information.

The absence of any news coverage in the last 48 hours makes it impossible to identify a concrete catalyst for ICG's sharp decline. Possible explanations for this type of move in a micro-cap NASDAQ stock could include technical selling pressure unrelated to fundamentals, a delayed or unindexed news event that hasn't yet reached major financial news feeds, sector rotation out of small-cap equities, or broader market conditions affecting low-volume stocks. Without access to SEC filings, press releases directly from the company, or confirmation of the specific trigger, any explanation remains speculative. The stock's position as the 22nd biggest loser suggests it moved in line with broader market weakness or sector-specific pressure rather than isolated company-specific news.

ZSTK

Flora Growth Corp.Financial Services

$1.82−$0.36

-16.5%

NASDAQ · Mkt cap $32 M

No news headlines were found in the last 48 hours, so the 16.51% drop cannot be attributed to a specific announced event. The decline likely stems from technical selling, market-wide pressure, or unannounced catalysts specific to Flora Growth's business.

Flora Growth Corp. suffered a sharp single-day loss with no corresponding news coverage in the provided recent headlines. This absence of reported catalysts makes it difficult to pinpoint a definitive cause. For a microcap cannabis-adjacent or specialty agricultural company like ZSTK, typical drivers of large single-day drops include sudden changes in regulatory sentiment, sector-wide selloffs in the cannabis or agricultural biotech space, unexpected insider selling or dilution announcements not yet picked up by major news feeds, analyst downgrades distributed through proprietary channels, or technical breakdown through key support levels triggering algorithmic selling. Without corroborating news or filings, attribution remains speculative.

LCID

Lucid Group, Inc.Consumer Cyclical

$4.62−$0.89

-16.2%

NASDAQ · Mkt cap $1.8 B

Lucid Group plunged 16.15% after bankruptcy and take-private rumors circulated on July 14, though the company denied the reports as "completely false" later the same day, limiting the final decline from intraday lows of 50-56%.

On July 14, 2026, reports emerged that Lucid had hired turnaround consultant AlixPartners and was weighing restructuring options including Chapter 11 bankruptcy or going private. The stock initially crashed 50% in afternoon trading. Lucid management responded swiftly with an official statement calling the reports "completely false" and clarifying that AlixPartners is only assisting the company with unspecified support, not recommending bankruptcy. The stock pared losses significantly after the denial, closing down 16.15%. The company also noted it held $700 million in cash at Q1-end and raised $1 billion in April. Underlying concerns appear related to Gravity SUV production issues that have pressured sales, but the headline catalyst was the unconfirmed bankruptcy speculation and its subsequent denial.

SLMT

Brera Holdings PLCCommunication Services

$5.56−$1.07

-16.1%

HUHU

HUHUTECH International Group Inc. Ordinary SharesIndustrials

$4.90−$0.93

-16.0%

NASDAQ · Mkt cap $127 M

No news headlines were found in the last 48 hours, so the 15.95% decline cannot be attributed to any reported corporate event, and the cause remains unknown without additional context.

HUHU experienced a significant one-day drop of nearly 16%, ranking it among the day's largest losers, yet no news coverage is available within the 48-hour window to explain the move. This creates a meaningful gap between the magnitude of the price action and the information trail. For a micro-cap or lower-liquidity NASDAQ stock like HUHU, moves of this size can result from several categories of catalyst: technical selling (profit-taking after a run, breach of support levels), market-wide sentiment shifts affecting its sector, delayed disclosure of negative developments, insider transactions, or analyst downgrades that may not immediately surface in aggregated RSS feeds. Without access to the stock's underlying business fundamentals, recent earnings calendar, or sector dynamics, assigning a specific cause would be speculative.

SBEV

Splash Beverage Group, Inc.Consumer Defensive

$0.10−$0.02

-15.9%

AMEX · Mkt cap $2.5 M

Splash Beverage announced a reverse stock split and balance sheet improvements on July 14, which typically signals financial distress and dilution concerns, likely driving the 15.89% intraday sell-off despite the framing as strategic transformation.

The company announced two actions today: a reverse stock split and balance sheet improvements with board approval. Reverse stock splits are often perceived negatively by market participants because they are frequently used by financially distressed companies to maintain exchange listing compliance when share prices fall below minimum thresholds. While management framed these actions as strengthening the company and continuing strategic transformation, the market interpreted the reverse split announcement as a red flag rather than positive news. The disconnect between the company's narrative and market reaction suggests investors view the reverse split as evidence of underlying weakness, not strength. The balance sheet improvement language is vague in the headline snippet and lacks specifics like earnings, revenue, or debt reduction metrics that would reassure investors.

SRXH

SRX Global Inc.Technology

$2.31−$0.43

-15.7%

NBIG

Leverage Shares 2x Long NBIS Daily ETF

$18.09−$3.34

-15.6%

NASDAQ

No news headlines available in the last 48 hours; the 15.59% decline in this 2x leveraged long ETF most likely reflects a sharp fall in its underlying index or tracking error amplification of broader market weakness.

NBIG is a leveraged 2x daily reset ETF tracking the Nasdaq Biotechnology Index (NBIS), meaning it amplifies daily moves of the underlying index by roughly two times. With no news identified in the last 48 hours, the decline appears to be driven by movement in the underlying biotech sector rather than a company-specific catalyst. The 15.59% drop is consistent with an ~7.8% decline in NBIS, which could result from sector-wide selloff, index constituent weakness, broader market volatility, or technical deleveraging. Leveraged ETFs also experience decay over time and can lag their target index during volatile periods, potentially explaining some portion of underperformance beyond simple 2x amplification.

NBIL

GraniteShares 2x Long NBIS Daily ETF

$26.08−$4.81

-15.6%

NASDAQ

No news headlines were found in the last 48 hours, but the 15.57% decline in this 2x leveraged long ETF most likely reflects a sharp drop in its underlying NBIS index or broad market weakness amplified by the fund's 2x daily reset mechanism.

NBIL is a daily leverage ETF that tracks twice the daily performance of the NBIS index. With no news coverage available in the timeframe provided, the sharp decline cannot be attributed to a specific company announcement, earnings miss, regulatory action, or sector-specific event. However, this type of security is structurally designed to amplify intraday moves in its underlying. A 15.57% drop suggests either a roughly 7.8% decline in NBIS itself on the day, or a combination of underlying weakness compounded by potential margin pressures or rebalancing mechanics inherent to leveraged ETFs. Without headline evidence of what moved NBIS, the cause could be broad market selloff, sector rotation, or index constituent weakness, but the mechanism amplifying the decline is clear: leverage applied to an unfavorable daily return in the underlying basket.

FRTT

Fort Technology Inc. Common SharesConsumer Cyclical

$0.87−$0.15

-15.0%

NASDAQ · Mkt cap $11 M

No news headlines were available in the last 48 hours for FRTT, so the 15% drop cannot be directly attributed to a published announcement or earnings report. The decline likely reflects either technical selling pressure, a delayed news event not yet indexed by Yahoo Finance, or broader market con…

The absence of recent news headlines makes root-cause attribution difficult. Fort Technology is a micro-cap stock trading under $1, which typically experiences higher volatility and is more susceptible to liquidity-driven moves, short covering, or small-scale institutional rebalancing that may not trigger immediate press coverage. For stocks in this category, sharp single-day declines often stem from delayed regulatory filings, insider transactions, sector-wide technical pullbacks, or unconfirmed social-media rumors that precede formal news releases. Without access to Level 2 order flow data, filing databases, or real-time trading chat, we cannot pinpoint the specific catalyst. The move could equally reflect profit-taking after a recent run, a failed financing attempt, or simply low trading volume amplifying normal price swings.

JTAI

Jet.AI Inc.Technology

$4.87−$0.86

-15.0%

NASDAQ · Mkt cap $2.4 M

Jet.AI announced a merger and data center spin-off on July 14, which likely triggered a 15% sell-off as the market processed dilution concerns, spin-off execution risk, and uncertainty about the post-transaction ownership structure.

On July 14, Jet.AI announced a letter of intent for a merger and a spin-off of its data center business, designed to create two public companies. This is a material corporate action that historically triggers volatility. The market's negative reaction likely reflects several concerns: shareholder dilution from the merger, the complexity and execution risk of separating and spinning off a business segment, uncertainty about the pro-forma capital structure and ownership percentages post-transaction, and the general risk that dual-company strategies underperform. The announcement came the day after Jet.AI closed a transaction with flyExclusive, suggesting rapid strategic shifts that may have amplified investor caution. Without detailed terms of the proposed merger, valuation impact, or spin-off mechanics from the headline excerpts, investors may be pricing in worst-case scenarios or simply selling first to avoid a liquidity event surprise.

PSNY

Polestar Automotive Holding UK PLCConsumer Cyclical

$15.31−$2.70

-15.0%

NASDAQ · Mkt cap $2.0 B

Polestar plunged 15% after reporting record first-half sales, primarily because the U.S. has banned the company from selling its EVs due to connected-vehicle technology linked to China, a critical market access issue that overshadows operational gains.

The headline reveals a direct and severe constraint on Polestar's growth: a U.S. sales ban tied to national security concerns about Chinese-connected technology. While the company reported record first-half sales, suggesting strong demand and operational execution, the market has penalized the stock sharply because the U.S. market represents a major growth opportunity for EV makers, and losing access to it undermines long-term revenue and valuation prospects. The disconnect between "record sales" and a 15% drop indicates that investors are weighing the ban's impact on future guidance and market potential as far more significant than current operational performance. This is a regulatory/geopolitical shock that affects the company's addressable market, not a misfire in execution.

SGLY

Singularity Future Technology Ltd.Industrials

$0.24−$0.04

-15.0%

NASDAQ · Mkt cap $2.7 M

No news headlines were published in the last 48 hours, making the 14.98% drop unexplained by recent announcements. The decline likely stems from technical selling, broader market weakness, or undisclosed company developments.

With zero headlines available for SGLY over the past two days, there is no news-based explanation for the substantial 14.98% decline that would make it the 34th biggest loser on the day. For a micro-cap stock trading at $0.24, typical catalysts include earnings reports, regulatory decisions, insider transactions, short-squeeze reversals, or changes in company guidance. Given the stock's penny-stock status and the absence of reported news, the move could reflect technical factors such as profit-taking after a prior rally, broad market conditions affecting small-caps, or delayed disclosure of company developments that haven't yet reached major news feeds. Without access to SEC filings, message boards, or real-time trading data, attributing the drop to a specific event is not possible based on the information provided.

CAST

FreeCast, Inc. Class A Common StockCommunication Services

$2.79−$0.49

-14.9%

NASDAQ · Mkt cap $100 M

FreeCast (CAST) fell 14.94% with no news headlines in the last 48 hours, so the cause remains unclear; the drop may reflect technical selling, sector headwinds, or unreported developments.

There are no recent news headlines available to explain the significant 14.94% single-day decline in CAST stock. Without a concrete catalyst from earnings, guidance, M&A activity, regulatory action, or management announcements, the most likely generic causes are: first, technical selling or profit-taking if the stock had run up prior to this snapshot date, or second, market-wide or streaming-sector weakness affecting small-cap media companies. FreeCast is a small-cap over-the-counter-like equity traded on NASDAQ with limited analyst coverage, so intraday moves can be driven by low liquidity, retail trading patterns, or news released through channels outside the Yahoo Finance RSS feed used here. Without access to press releases, social media, or other real-time data, we cannot definitively attribute the move.

XCH

XCHG Limited American Depositary ShareIndustrials

$0.66−$0.12

-14.9%

NASDAQ · Mkt cap $21 M

No news headlines were found in the last 48 hours, so the 14.91% drop cannot be directly attributed to a reported event. The decline likely stems from technical selling, sector weakness, or unreported developments.

XCH dropped nearly 15% on 2026-07-14 with zero news coverage in the preceding 48 hours according to the Yahoo Finance feed provided. This absence of reported catalysts makes pinpointing a cause difficult. For a micro-cap or thinly traded American Depositary Share, declines of this magnitude can occur due to several factors: technical breakdown below key support levels, sector-wide liquidation, dividend cuts or distributions not yet widely reported, short-seller activity, or delayed announcement of earnings misses or guidance reductions. Without access to earnings calendars, insider trades, or real-time market commentary beyond the provided headlines, we cannot determine whether this was driven by company-specific fundamentals or broader market conditions affecting emerging markets or the security's home country.

NTHI

Neonc Technologies Holdings, Inc.Healthcare

$3.68−$0.64

-14.8%

NASDAQ · Mkt cap $120 M

No news headlines were available in the last 48 hours, so the 14.81% decline cannot be attributed to a specific announced event. The drop likely reflects either technical selling pressure, delayed market reaction to older news, or sector-wide weakness affecting this small-cap stock.

The absence of recent news headlines in the search results means we cannot point to an earnings miss, product announcement, regulatory action, or other specific catalyst for today's sharp decline. For a small-cap stock like NTHI trading at $3.68, price moves of this magnitude are not uncommon and can be driven by several typical categories: broad market selling or sector rotation, changes in sentiment among retail or institutional holders, technical breakdown through support levels, or delayed digestion of news that may have been published outside the 48-hour window. Without access to older headlines, press releases, or intraday developments, attribution remains speculative. The stock's position as the 37th biggest loser suggests the move was notable but not unprecedented in daily volatility terms.

SKYQ

Sky Quarry Inc.Energy

$3.40−$0.59

-14.8%

NASDAQ · Mkt cap $12 M

Sky Quarry Inc. fell 14.79% on July 14, 2026, but no news headlines from the last 48 hours are available to identify the specific cause of the decline.

The absence of recent headlines creates a genuine constraint on root-cause attribution. A 14.79% single-day drop for a micro-cap stock trading at $3.40 typically correlates with one of several catalyst types: earnings disappointment or a missed guidance revision, a material business development reversal, sector-wide pressure affecting quarry or mining operations, insider selling or dilutive equity issuance, or a delayed negative announcement that may have circulated outside mainstream financial news feeds. Without access to the company's SEC filings, press releases, or social media channels on the snapshot date, the specific trigger remains indeterminate. Quarrying and aggregate extraction businesses are cyclical and sensitive to construction demand, regulatory changes, and input cost inflation, any of which could have shifted unexpectedly.

SUNE

SUNation Energy Inc.Technology

$2.90−$0.50

-14.7%

NASDAQ · Mkt cap $9.2 M

No news headlines were found in the last 48 hours to explain the 14.71% drop in SUNE stock, so the cause remains unclear from available public sources.

SUNation Energy Inc. experienced a significant single-day decline of 14.71% with no corresponding news headlines in the last 48 hours to account for the move. This disconnect suggests either a delayed market reaction to older news, technical selling pressure, sector-wide headwinds in renewable energy, or an undetected announcement not yet captured by the RSS feed. Solar and renewable energy stocks can be volatile and sensitive to broader energy market sentiment, interest rate expectations, and policy developments. Without fresh fundamental news linked to the company itself, the drop could reflect technical factors such as options expiration, short covering reversal, or momentum-driven selling that hit the stock as the 39th biggest loser of the day.

BIYA

Baiya International Group Inc.Technology

$3.50−$0.60

-14.6%

NASDAQ · Mkt cap $71 M

No news headlines were found in the last 48 hours for BIYA, so the 14.63% drop on July 14 cannot be attributed to any publicly disclosed catalyst. The decline likely reflects technical selling, market sentiment, or undisclosed developments.

The absence of recent news headlines makes it impossible to pinpoint a specific catalyst for BIYA's sharp 14.63% decline on July 14, 2026. For a micro-cap or lower-liquidity NASDAQ stock like BIYA, drops of this magnitude can occur from several categories of causes: technical momentum reversals or margin calls in a thin trading environment, delayed news that has not yet propagated to major RSS feeds, sector rotation out of the stock's industry segment, or deterioration in broader market sentiment toward that business category. Without access to company filings, insider transactions, or real-time market microstructure data, we cannot distinguish between these scenarios. The lack of contemporaneous headlines is itself notable and suggests either that no material news was released, or that any news has not yet surfaced in the sources monitored.

NXTS

Nexentis Technologies Inc.Basic Materials

$2.66−$0.45

-14.5%

DNLI

Denali Therapeutics Inc.Healthcare

$22.65−$3.83

-14.5%

NASDAQ · Mkt cap $3.6 B

Denali dropped 14.46% likely due to competitive pressure in Alzheimer's research, as Biogen is presenting Phase 2 data for its diranersen drug, which may overshadow or compete with Denali's own neurodegeneration pipeline.

The only relevant headline in the past 48 hours concerns Biogen presenting detailed Phase 2 study data for diranersen, an experimental Alzheimer's drug, at a London conference. While this news does not directly mention Denali, it is plausible that positive or notable results from a competing Alzheimer's therapeutic could reduce investor optimism for other players in the neurodegenerative disease space, including Denali. Denali's pipeline includes programs targeting neurodegeneration, so a strong clinical readout from a rival could shift capital away. However, the headline does not specify the nature of Biogen's data or market reception, nor does it explicitly reference Denali. The 14.46% drop is substantial enough to warrant a concrete catalyst, but without confirmation that the market reacted negatively to Biogen's presentation or that Denali issued guidance, guidance cuts, or clinical setbacks of its own, some of this remains inference.

Sweetgreen, Inc.Consumer Cyclical

$7.09−$1.18

-14.3%

NYSE · Mkt cap $795 M

Sweetgreen dropped 14.27% likely due to contagion risk from a major food safety crisis affecting the broader casual dining sector, specifically a parasite outbreak that has sickened thousands and prompted Taco Bell to remove ingredients at select locations.

The only headline provided reports a parasite outbreak spreading across the US that has sickened thousands, prompting Taco Bell to remove ingredients at select restaurants as a precaution. While the news directly names Taco Bell rather than Sweetgreen, the outbreak affects the broader casual dining and quick-service restaurant sector where food safety is paramount to consumer confidence and brand reputation. Investors in restaurant stocks often trade on sector-wide contagion during food safety crises, as similar outbreaks can emerge at competing chains or supply chains may overlap. SG's 14.27% loss on the same day the outbreak news circulated suggests market participants are pricing in reputational risk, potential customer avoidance of casual dining generally, or concern that Sweetgreen's supply chain could be similarly affected. Without direct news linking Sweetgreen to the outbreak, the connection is inference based on sector dynamics rather than company-specific reporting.

GRML

Greenland Mines Ltd.Basic Materials

$0.18−$0.03

-14.2%

WYFI

WhiteFiber, Inc. Ordinary SharesTechnology

$31.13−$5.16

-14.2%

NASDAQ · Mkt cap $730 M

No news headlines were found in the last 48 hours, so the 14.22% drop cannot be directly attributed to a reported announcement or earnings release; the catalyst remains unclear without additional reporting.

The complete absence of recent news makes it difficult to pinpoint the precise cause of WYFI's sharp 14.22% decline on July 14, 2026. For a fiber/broadband infrastructure play like WhiteFiber, typical catalysts for large single-day drops include negative earnings surprises, reduced guidance, loss of a major contract, competitive announcements, or macroeconomic shifts affecting capital spending or borrowing costs. The stock's rank as the 45th biggest loser suggests sector-wide weakness is unlikely to be the sole driver. Possible explanations include unannounced insider selling, a delayed news release not yet indexed by Yahoo Finance, short covering reversal, or market reaction to secondary offering rumors or regulatory concerns specific to broadband operators.

OFAL

OFA GroupIndustrials

$0.14−$0.02

-13.9%

NASDAQ · Mkt cap $2.5 M

OFA Group announced strong commercial validation and rapid adoption of its AI platform QikBIM on the same day the stock dropped 13.93%, suggesting the positive news failed to meet market expectations or was overshadowed by profit-taking, valuation concerns, or broader sector headwinds.

The headline released on July 14 at 12:00 UTC describes strong early commercial validation, rapid platform registrations, and accelerating global user adoption for OFA's AI platform QikBIM. This is ostensibly positive news. However, the stock fell sharply the same day it was announced, which is counterintuitive. Several explanations are plausible: the market may have expected even stronger metrics or revenue guidance; early user registrations do not guarantee monetization or profitability; investors may view the announcement as promotional rather than substantive; or the stock may have been subject to profit-taking after a prior run-up. Alternatively, sector-wide AI or tech weakness, short covering, or unrelated financial deterioration could have driven the move. Without earnings data, guidance, or context on the stock's recent price history, the disconnect between positive narrative and negative price action remains unexplained.

VTAK

Catheter Precision, Inc.Healthcare

$0.56−$0.09

-13.9%

AMEX · Mkt cap $770 K

No news headlines were found in the last 48 hours to explain the 13.90% drop in VTAK stock, so the cause remains unclear without additional context or market-wide factors.

Catheter Precision Inc trades on the AMEX as a small-cap medical device company, and a sharp intraday decline of nearly 14% with zero news coverage in the prior 48 hours is atypical for a fundamental catalyst-driven move. The absence of headlines means we cannot point to earnings disappointment, FDA action, clinical trial results, partnership announcements, or guidance changes. For a micro-cap stock like this, possible explanations include technical selling or a wave of redemptions, a delayed press release not yet picked up by Yahoo Finance, insider selling activity, or broader sector weakness in medical devices. Without additional reporting, the root cause is speculative. Small-cap stocks on regional exchanges can experience sharp moves on modest trading volume or algorithmic activity unrelated to company fundamentals.

BYAH

Park Ha Biological Technology Co., Ltd. Ordinary SharesConsumer Defensive

$0.40−$0.06

-13.8%

NASDAQ · Mkt cap $2.4 M

No news headlines were published in the last 48 hours for BYAH, so the 13.77% decline cannot be attributed to any identified catalyst. The drop likely reflects technical selling, market sentiment, or undisclosed company developments.

The absence of recent news headlines in the Yahoo Finance RSS feed means no specific fundamental catalyst can be identified for today's sharp 13.77% decline in BYAH stock. For a micro-cap biotech company trading at $0.40 per share, price movements of this magnitude can be driven by several non-news factors: technical selling pressure or support level breaks, reduced trading liquidity amplifying normal volume swings, short-seller activity, or delayed announcement dissemination that has not yet been indexed by major financial news aggregators. Biotech stocks at this price point are inherently volatile and can gap down on regulatory delays, preclinical trial setbacks, or clinical hold notifications that may not immediately appear in mainstream financial feeds. Without identifying headlines or real-time trading data, it is impossible to determine whether this move is random volatility or reflects a meaningful company-specific event.

CMCT

Creative Media & Community Trust CorporationReal Estate

$2.82−$0.45

-13.8%

NASDAQ · Mkt cap $15 M

No news headlines were found in the last 48 hours to explain the 13.76% drop in CMCT, making the specific catalyst unclear without additional market information.

The absence of any recent news headlines is notable for a stock that ranks among the day's 49 biggest losers. For a real estate investment trust like Creative Media & Community Trust, typical catalysts for sharp single-day declines include dividend cuts or suspensions, unexpected earnings misses, analyst downgrades, sector-wide weakness in retail or entertainment real estate, or covenant violations. Since no headlines are available, the decline could stem from intraday technical selling, delayed publication of news not yet indexed by the RSS feed, sector rotation out of retail or entertainment assets, broader market deterioration, or accumulation of negative sentiment from previous trading sessions. Without corroborating headlines or statements from the company, attribution remains speculative.

QTTB

Q32 Bio Inc.Healthcare

$18.46−$2.92

-13.7%

NASDAQ · Mkt cap $472 M

Q32 Bio announced a proposed stock offering on July 13 after its alopecia drug trial data sparked an 83% surge; the offering likely triggered profit-taking and dilution concerns that reversed the gain, leaving the stock down 13.66% despite positive clinical results.

The headline sequence reveals a classic biotech pattern. On July 13, Q32 Bio released positive Phase 2a trial data showing 35.3% mean reduction in hair loss scores, sparking an 83% intraday surge. However, the company simultaneously announced a proposed public offering of common stock and pre-funded warrants. While the trial results were genuinely positive and warranted analyst upgrades with 200% upside targets, the equity offering announcement triggered immediate profit-taking and shareholder concern over dilution. The July 14 snapshot captures the aftermath: initial euphoria has reversed into a 13.66% loss, suggesting investors chose to lock in gains rather than hold through a dilution event. This is typical behavior when clinical catalysts coincide with capital raises.